CN102172356A - Use of taurochenodeoxycholic acid in prevention and treatment of osteoporosis - Google Patents
Use of taurochenodeoxycholic acid in prevention and treatment of osteoporosis Download PDFInfo
- Publication number
- CN102172356A CN102172356A CN2011100507563A CN201110050756A CN102172356A CN 102172356 A CN102172356 A CN 102172356A CN 2011100507563 A CN2011100507563 A CN 2011100507563A CN 201110050756 A CN201110050756 A CN 201110050756A CN 102172356 A CN102172356 A CN 102172356A
- Authority
- CN
- China
- Prior art keywords
- taurochenodeoxycholic acid
- osteoporosis
- group
- acid
- taurochenodeoxycholic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Abstract
The invention relates to new use of taurochenodeoxycholic acid, in particular to the new use of the taurochenodeoxycholic acid in prevention and treatment of osteoporosis. Through the study on taurochenodeoxycholic acid, the inventor found that the taurochenodeoxycholic acid can promote bone cells to secrete osteocalcin and improve lowered bone density. Thus, the taurochenodeoxycholic acid can be used in prevention or treatment of osteoporosis. After being administrated directly or being formed into various formulations, the taurochenodeoxycholic acid can be used for preventing or treating osteoporosis and other related diseases or states of osteoporosis.
Description
Technical field
The present invention relates to a kind of new application of Taurochenodeoxycholic Acid, be specifically related to Taurochenodeoxycholic Acid in the new purposes of preventing and treating on the osteoporosis.
Background technology
(Taurochenodeoxycholic Acid TCDCA) is the conjugated bile acids that mainly is present in the animal biles such as chicken, duck, goose, cattle, sheep, Serpentis to Taurochenodeoxycholic Acid.Its chemical name is 3 α, 7 alpha-dihydroxy-s-5 β-24-cholane acyl-N-taurine, and structural formula is as follows:
It is by taurine (Taur ine, Tau) and chenodeoxycholic acid (molecular formula is C for Chenodeoxycholic acid, CDCA) the extremely bitter acid compound of the odorless that forms, white powder, flavor that combines
23(OH)
2H
37CONHCH
2CH
2SO
3H, relative molecular mass are 499.69.TCDCA has characteristics such as medicament sources is extensive, safe, effective as a kind of main component in the bile.Present discover TCDCA have antiinflammatory (Li Peifeng, Cao Jinshan, Guan Hong etc. Chinese veterinarian's medical magazine, 2002,21 (1): 7-10), body fluid and cellular immunization regulate (Shi Youfei, Li Peifeng, Li Jinlian etc. the Chinese Pharmacological circular, 2007,23 (7): 859-864), anti-intestinal epithelial cell apoptosis (Turner DJ, Alaish SM, Zou T, et al.Ann Surg.2007,245 (3): 415-25) etc.
Osteoporosis (Osteoporsis OP) is the human endocrine Developmental and Metabolic Disorder, constantly reduces with bone ore deposit composition and bone matrix equal proportion, and the sclerotin attenuation, bone trabecula quantity reduces, and bone fragility increases to a kind of general skeletal diseases of feature.Clinical manifestation is a lumbago and backache, is easy to fracture.The patient of this disease is mainly most of postmenopausal women and old people, and the whole world has 200,000,000 people to suffer from osteoporosis approximately at present, and China has patients with osteoporosis more than 8,000 ten thousand now.Along with the process of social population's aging is constantly aggravated, the osteoporosis disease has become a serious social public health problem.The osteoporotic method of existing control generally is Drug therapy, bone peptide sheet, calcitonin or the alendronate etc. of mainly containing commonly used, and said medicine can promote osteogenesis; Also have to adopt and directly replenish calcium preparation,, have the drawback that price is higher or side effect is more of taking medicine for a long time, can not satisfy the osteoporotic requirement of control well though above-mentioned method has certain effect to fill up the part of bone-loss.
Summary of the invention
The inventor is through long-term research to Taurochenodeoxycholic Acid; the inventor is by discovering that to Taurochenodeoxycholic Acid it can promote osteoblast secretion Bone Gla protein; and can improve the bone density that has reduced; and then be applied to prevent and treat osteoporosis; directly administration also can be made into various dosage forms and be used to prevent or treat osteoporosis or other diseases or the state relevant with it.
The invention provides Taurochenodeoxycholic Acid in prevention or prevent and treat application on the osteoporosis; directly administration; can be principal agent also, cooperate other adjuvants to prepare the medicine of various dosage forms such as injection, tablet, powder, granule, capsule, oral agents with it.
The inventor finds by experiment, when directly by oral administration, can significantly promote osteoblast secretion Bone Gla protein, and Bone Gla protein is a kind of noncollagen protein of emiocytosis in the osteogenetic process, is Ca
2+Combine with hydroxyapatite, the essential composition of sclerotin mineralising.Cell with osteogenic activity can produce Bone Gla protein in the maturation period in later stage.Because the Bone Gla protein secretion level is the embodiment of Oesteoblast growth and function status, is osteoplastic sign.So, promoted the secretion of Bone Gla protein, illustrate and improved osteoblastic vigor, help the formation of bone.In addition; Taurochenodeoxycholic Acid can improve the bone density by the osteoporosis model of dexamethasone preparation; because this model has general representativeness, confirmed that Taurochenodeoxycholic Acid can improve the bone density that has reduced, and then confirmed that it is in the application that prevents and treats on the osteoporosis.
In addition; the inventor also finds; when in food or feedstuff, directly adding Taurochenodeoxycholic Acid; by normal feed digestion process; also can promote osteoblast secretion Bone Gla protein to improve bone density; therefore also can adopt the above-mentioned form of mixtures that contains Taurochenodeoxycholic Acid, prevent and treat osteoporosis such as forms such as health foods.
By above-mentioned research, the present invention is for prevention or prevent and treat osteoporosis, and a brand-brand-new way is provided, and then provides technical foundation for the exploitation of a series of control medicine for treating osteoporosis.Taurochenodeoxycholic Acid is as the effective ingredient of animal body, and its untoward reaction is little, as the medicine of replenishing the calcium, can prevent and treat the osteoporosis disease by life-time service.
Description of drawings
Fig. 1-5 takes the photograph sheet for X line among the embodiment 2 and estimates Taurochenodeoxycholic Acid to the osteoporotic comparison chart that influences; Wherein Fig. 1 is a normal group X line sketch map; Fig. 2 is a model group X line sketch map; Fig. 3 is a low dose group X line sketch map; Fig. 4 is middle dosage group X line sketch map, and Fig. 5 is a high dose group X line sketch map.
The specific embodiment
Embodiment 1
Be divided into normal group, model group and low dosage, middle dosage, three administration groups of high dose during experiment, every group is 10 mices.Normal group only gavages distilled water; It is that the 20mg/kg dexamethasone carries out subcutaneous injection to mice that model group adopts dosage, every injection in a day once, continues 14 days, preparation mice osteoporosis model; The administration after model preparation is finished of administration group, administration group TCDCA dosage are respectively 0.05,0.1 and 0.2g/kg, and route of administration is a gastric infusion, every day 1 time, successive administration 7 days.
Normal group, model group and administration group are carried out the blood sampling of eyeball venous plexus, adopt radioimmunology to detect BGP content in the mice serum, the results are shown in Table 1.Low, middle dosage group is compared with normal group, has improved serum osteocalcin content significantly; Basic, normal, high dosage group is compared with model group, but the utmost point improves serum osteocalcin content significantly.
Table 1TCDCA is to the influence of mice serum Bone Gla protein
Annotate: * represents and normal group comparing difference remarkable (P＜0.05); * represents and the poor heteropole of normal group remarkable (P＜0.01); △ represents and model group comparing difference remarkable (P＜0.05); △ △ represents and the poor heteropole of model group remarkable (P＜0.01).
Embodiment 2
Be divided into normal group, model group and low dosage, middle dosage, three administration groups of high dose during experiment, every group is 10 mices.Normal group only gavages distilled water; It is that the 20mg/kg dexamethasone carries out subcutaneous injection to mice that model group adopts dosage, every injection in a day once, continues 14 days, preparation mice osteoporosis model; The administration after model preparation is finished of administration group, administration group TCDCA dosage are respectively 0.05,0.1 and 0.2g/kg, and route of administration is a gastric infusion, every day 1 time, successive administration 7 days.
Normal group, model group and administration group mice are carried out the X line take the photograph sheet, see Fig. 1-5.Use the ImageJ image analysis software and measure the gray value of mice left side and right side femur, the gray value on the X line can reflect bone density indirectly.The results are shown in Table 2.As can be seen, basic, normal, high dosage group is compared with model group, and the utmost point promotes the model group bone density to recover significantly.
Table 2TCDCA is to the influence of mouse femur bone density
Annotate: * represents and normal group comparing difference remarkable (P＜0.05); * represents and the poor heteropole of normal group remarkable (P＜0.01); △ represents and model group comparing difference remarkable (P＜0.05); △ △ represents and the poor heteropole of model group remarkable (P＜0.01).
Claims (5)
1. Taurochenodeoxycholic Acid is in the application that prevents and treats on the osteoporosis, and the structural formula of described Taurochenodeoxycholic Acid is as follows:
2. application according to claim 1 is characterized in that: Taurochenodeoxycholic Acid is used to promote osteoblast secretion Bone Gla protein.
3. application according to claim 1 is characterized in that: Taurochenodeoxycholic Acid is used to improve bone density.
4. one kind is used to prevent and treat osteoporotic medicinal mixture, it is characterized in that: contain Taurochenodeoxycholic Acid in the component.
5. one kind is used to prevent and treat osteoporotic mixture, it is characterized in that: contain Taurochenodeoxycholic Acid in the component.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110050756 CN102172356B (en) | 2011-03-03 | 2011-03-03 | Use of taurochenodeoxycholic acid in prevention and treatment of osteoporosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201110050756 CN102172356B (en) | 2011-03-03 | 2011-03-03 | Use of taurochenodeoxycholic acid in prevention and treatment of osteoporosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102172356A true CN102172356A (en) | 2011-09-07 |
| CN102172356B CN102172356B (en) | 2013-04-03 |
Family
ID=44515733
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201110050756 Expired - Fee Related CN102172356B (en) | 2011-03-03 | 2011-03-03 | Use of taurochenodeoxycholic acid in prevention and treatment of osteoporosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102172356B (en) |
Cited By (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013040265A1 (en) * | 2011-09-13 | 2013-03-21 | Brigham Young University Technology Commercialization Office | Compositions for treating bone diseases and broken bones |
| CN104080459A (en) * | 2011-09-13 | 2014-10-01 | 布莱阿姆青年大学 | Compositions for treating bone diseases and broken bones |
| US9314472B2 (en) | 2012-10-17 | 2016-04-19 | Brigham Young University | Treatment and prevention of mastitis |
| US9345655B2 (en) | 2011-12-21 | 2016-05-24 | Brigham Young University | Oral care compositions |
| US9387215B2 (en) | 2013-04-22 | 2016-07-12 | Brigham Young University | Animal feed including cationic cholesterol additive and related methods |
| US9434759B1 (en) | 2015-05-18 | 2016-09-06 | Brigham Young University | Cationic steroidal antimicrobial compounds and methods of manufacturing such compounds |
| US9533063B1 (en) | 2012-03-01 | 2017-01-03 | Brigham Young University | Aerosols incorporating ceragenin compounds and methods of use thereof |
| US9546195B2 (en) | 2011-07-20 | 2017-01-17 | Brigham Young University | Hydrophobic ceragenin compounds and devices incorporating same |
| US9603859B2 (en) | 2011-09-13 | 2017-03-28 | Brigham Young University | Methods and products for increasing the rate of healing of tissue wounds |
| US9686966B2 (en) | 2014-04-30 | 2017-06-27 | Brigham Young University | Methods and apparatus for cleaning or disinfecting a water delivery system |
| US9694019B2 (en) | 2011-09-13 | 2017-07-04 | Brigham Young University | Compositions and methods for treating bone diseases and broken bones |
| US9867836B2 (en) | 2014-03-13 | 2018-01-16 | Brigham Young University | Lavage and/or infusion using CSA compounds for increasing fertility in a mammal |
| US9931350B2 (en) | 2014-03-14 | 2018-04-03 | Brigham Young University | Anti-infective and osteogenic compositions and methods of use |
| US9943529B2 (en) | 2013-01-07 | 2018-04-17 | Brigham Young University | Methods for reducing cellular proliferation and treating certain diseases |
| US9943614B2 (en) | 2008-06-17 | 2018-04-17 | Brigham Young University | Cationic steroid antimicrobial diagnostic, detection, screening and imaging methods |
| US10039285B2 (en) | 2012-05-02 | 2018-08-07 | Brigham Young University | Ceragenin particulate materials and methods for making same |
| US10155788B2 (en) | 2014-10-07 | 2018-12-18 | Brigham Young University | Cationic steroidal antimicrobial prodrug compositions and uses thereof |
| US10220045B2 (en) | 2014-03-13 | 2019-03-05 | Brigham Young University | Compositions and methods for forming stabilized compositions with reduced CSA agglomeration |
| US10227376B2 (en) | 2014-08-22 | 2019-03-12 | Brigham Young University | Radiolabeled cationic steroid antimicrobials and diagnostic methods |
| US10226550B2 (en) | 2016-03-11 | 2019-03-12 | Brigham Young University | Cationic steroidal antimicrobial compositions for the treatment of dermal tissue |
| US10238665B2 (en) | 2014-06-26 | 2019-03-26 | Brigham Young University | Methods for treating fungal infections |
| US10370403B2 (en) | 2015-04-22 | 2019-08-06 | Brigham Young University | Methods for the synthesis of ceragenins |
| US10441595B2 (en) | 2014-06-26 | 2019-10-15 | Brigham Young University | Methods for treating fungal infections |
| US10568893B2 (en) | 2013-03-15 | 2020-02-25 | Brigham Young University | Methods for treating inflammation, autoimmune disorders and pain |
| US10626139B2 (en) | 2014-02-27 | 2020-04-21 | Brigham Young University | Cationic steroidal antimicrobial compounds |
| US10959433B2 (en) | 2017-03-21 | 2021-03-30 | Brigham Young University | Use of cationic steroidal antimicrobials for sporicidal activity |
| US11286276B2 (en) | 2014-01-23 | 2022-03-29 | Brigham Young University | Cationic steroidal antimicrobials |
| CN115531396A (en) * | 2022-10-21 | 2022-12-30 | 大连医科大学附属第一医院 | Application of cholic acid substance in preparation of medicine for inhibiting osteoclast differentiation |
| US11739116B2 (en) | 2013-03-15 | 2023-08-29 | Brigham Young University | Methods for treating inflammation, autoimmune disorders and pain |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9527883B2 (en) | 2015-04-22 | 2016-12-27 | Brigham Young University | Methods for the synthesis of ceragenins |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101028509A (en) * | 2006-03-03 | 2007-09-05 | 石朝周 | Snake gallbladder for artificial medicine |
| CN101862311A (en) * | 2010-06-08 | 2010-10-20 | 崔浩 | Penetration promoting and eyesight improving eye drop |
| CN102178684A (en) * | 2011-03-03 | 2011-09-14 | 山东农业大学 | Application of taurochenodeoxycholic acid in preventing and treating adverse reactions of glucocorticoid medicaments |
-
2011
- 2011-03-03 CN CN 201110050756 patent/CN102172356B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101028509A (en) * | 2006-03-03 | 2007-09-05 | 石朝周 | Snake gallbladder for artificial medicine |
| CN101862311A (en) * | 2010-06-08 | 2010-10-20 | 崔浩 | Penetration promoting and eyesight improving eye drop |
| CN102178684A (en) * | 2011-03-03 | 2011-09-14 | 山东农业大学 | Application of taurochenodeoxycholic acid in preventing and treating adverse reactions of glucocorticoid medicaments |
Non-Patent Citations (1)
| Title |
|---|
| 何秀玲等: "牛磺鹅去氧胆酸研究进展", 《畜牧与饲料科学》, no. 03, 30 May 2008 (2008-05-30) * |
Cited By (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9943614B2 (en) | 2008-06-17 | 2018-04-17 | Brigham Young University | Cationic steroid antimicrobial diagnostic, detection, screening and imaging methods |
| US10676501B2 (en) | 2011-07-20 | 2020-06-09 | Brigham Young University | Hydrogel materials incorporating eluting ceragenin compound |
| US9546195B2 (en) | 2011-07-20 | 2017-01-17 | Brigham Young University | Hydrophobic ceragenin compounds and devices incorporating same |
| US9694019B2 (en) | 2011-09-13 | 2017-07-04 | Brigham Young University | Compositions and methods for treating bone diseases and broken bones |
| CN104080459A (en) * | 2011-09-13 | 2014-10-01 | 布莱阿姆青年大学 | Compositions for treating bone diseases and broken bones |
| US9155746B2 (en) | 2011-09-13 | 2015-10-13 | Brigham Young University | Compositions and methods for treating bone diseases and broken bones |
| US9161942B2 (en) | 2011-09-13 | 2015-10-20 | Brigham Young University | Methods and products for increasing the rate of healing of tissue wounds |
| WO2013040265A1 (en) * | 2011-09-13 | 2013-03-21 | Brigham Young University Technology Commercialization Office | Compositions for treating bone diseases and broken bones |
| CN104080459B (en) * | 2011-09-13 | 2018-07-03 | 布莱阿姆青年大学 | For treating the composition of bone disease and knochenbruch |
| US9603859B2 (en) | 2011-09-13 | 2017-03-28 | Brigham Young University | Methods and products for increasing the rate of healing of tissue wounds |
| US9345655B2 (en) | 2011-12-21 | 2016-05-24 | Brigham Young University | Oral care compositions |
| US9533063B1 (en) | 2012-03-01 | 2017-01-03 | Brigham Young University | Aerosols incorporating ceragenin compounds and methods of use thereof |
| US10039285B2 (en) | 2012-05-02 | 2018-08-07 | Brigham Young University | Ceragenin particulate materials and methods for making same |
| US9314472B2 (en) | 2012-10-17 | 2016-04-19 | Brigham Young University | Treatment and prevention of mastitis |
| US10195215B2 (en) | 2013-01-07 | 2019-02-05 | Brigham Young University | Methods for reducing cellular proliferation and treating certain diseases |
| US9943529B2 (en) | 2013-01-07 | 2018-04-17 | Brigham Young University | Methods for reducing cellular proliferation and treating certain diseases |
| US11739116B2 (en) | 2013-03-15 | 2023-08-29 | Brigham Young University | Methods for treating inflammation, autoimmune disorders and pain |
| US10568893B2 (en) | 2013-03-15 | 2020-02-25 | Brigham Young University | Methods for treating inflammation, autoimmune disorders and pain |
| US9387215B2 (en) | 2013-04-22 | 2016-07-12 | Brigham Young University | Animal feed including cationic cholesterol additive and related methods |
| US11286276B2 (en) | 2014-01-23 | 2022-03-29 | Brigham Young University | Cationic steroidal antimicrobials |
| US10626139B2 (en) | 2014-02-27 | 2020-04-21 | Brigham Young University | Cationic steroidal antimicrobial compounds |
| US9867836B2 (en) | 2014-03-13 | 2018-01-16 | Brigham Young University | Lavage and/or infusion using CSA compounds for increasing fertility in a mammal |
| US10220045B2 (en) | 2014-03-13 | 2019-03-05 | Brigham Young University | Compositions and methods for forming stabilized compositions with reduced CSA agglomeration |
| US9931350B2 (en) | 2014-03-14 | 2018-04-03 | Brigham Young University | Anti-infective and osteogenic compositions and methods of use |
| US9686966B2 (en) | 2014-04-30 | 2017-06-27 | Brigham Young University | Methods and apparatus for cleaning or disinfecting a water delivery system |
| US10238665B2 (en) | 2014-06-26 | 2019-03-26 | Brigham Young University | Methods for treating fungal infections |
| US10441595B2 (en) | 2014-06-26 | 2019-10-15 | Brigham Young University | Methods for treating fungal infections |
| US10227376B2 (en) | 2014-08-22 | 2019-03-12 | Brigham Young University | Radiolabeled cationic steroid antimicrobials and diagnostic methods |
| US10155788B2 (en) | 2014-10-07 | 2018-12-18 | Brigham Young University | Cationic steroidal antimicrobial prodrug compositions and uses thereof |
| US10370403B2 (en) | 2015-04-22 | 2019-08-06 | Brigham Young University | Methods for the synthesis of ceragenins |
| US9434759B1 (en) | 2015-05-18 | 2016-09-06 | Brigham Young University | Cationic steroidal antimicrobial compounds and methods of manufacturing such compounds |
| US11253634B2 (en) | 2016-03-11 | 2022-02-22 | Brigham Young University | Cationic steroidal antibiotic compositions for the treatment of dermal tissue |
| US10226550B2 (en) | 2016-03-11 | 2019-03-12 | Brigham Young University | Cationic steroidal antimicrobial compositions for the treatment of dermal tissue |
| US10959433B2 (en) | 2017-03-21 | 2021-03-30 | Brigham Young University | Use of cationic steroidal antimicrobials for sporicidal activity |
| CN115531396A (en) * | 2022-10-21 | 2022-12-30 | 大连医科大学附属第一医院 | Application of cholic acid substance in preparation of medicine for inhibiting osteoclast differentiation |
| CN115531396B (en) * | 2022-10-21 | 2024-02-09 | 大连医科大学附属第一医院 | Application of cholic acid substance in preparation of medicines for inhibiting osteoclast differentiation |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102172356B (en) | 2013-04-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102172356B (en) | Use of taurochenodeoxycholic acid in prevention and treatment of osteoporosis | |
| JPH06502863A (en) | Two-component osteoporosis drug | |
| CN105903003B (en) | Composition for improving disuse osteoporosis and application thereof | |
| CN104736161A (en) | Preparation and method for the prophylaxis and treatment of atypical osteoporosis | |
| JPH0873376A (en) | Therapeutic agent for osteoporosis | |
| Manuele et al. | The teriparatide in the treatment of severe senile osteoporosis | |
| US20210253663A1 (en) | Novel pth mimetic peptide based on protein domain reconstruction and application thereof | |
| CN101244151A (en) | Medicament for treating dysentery | |
| Mittleman et al. | Thyrocalcitonin activity in hypercalcemia produced by calcium salts, parathyroid hormone and vitamin D | |
| US20040208916A1 (en) | Patch for the transdermal administration of beneficial substances | |
| CN102178684A (en) | Application of taurochenodeoxycholic acid in preventing and treating adverse reactions of glucocorticoid medicaments | |
| CN105169394A (en) | Medicine composite for treating osteoporosis and preparation method thereof | |
| CN109223771B (en) | Application of brucine A in preparing medicine for preventing and treating osteoporosis | |
| JP2003095974A (en) | Composite medicine for safely stimulating osteoplasty | |
| Garcia et al. | 7-week aerobic exercise training reduces adipocyte area and improves insulin sensitivity in Wistar rats fed a highly palatable diet | |
| RU2132188C1 (en) | Method of treating thyroid gland hypofunction | |
| RU2624170C2 (en) | Calves gastroenteritis treatment method | |
| RU2406545C2 (en) | Method of two-level epidural anesthesia | |
| US8182847B1 (en) | Methods and compositions to enhance endogenous IGF production and their uses | |
| CN112972658A (en) | Oral pharmaceutical composition of growth hormone or its analogue | |
| EP2289555A1 (en) | Method of treating frailty | |
| RU2392942C1 (en) | Method of treating osteohondritis deformans juvenilis of hip | |
| WO2005074944A1 (en) | Use of sodium neridronate to promote new bone formation | |
| JP2017002043A (en) | Medicine for treating or preventing nerve injury | |
| RU2134582C1 (en) | Method of stimulation of hepatic tissue regeneration |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130403 Termination date: 20170303 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |